30
participants completed the study
2 weeks
31 enrolled; women ages 19-69.
SeneGenceReview2-Week Ophthalmologist-Observed Safety Study
SeneGence® EyeCrème
Eye-area care, tested with clinical precision.
In an independent two-week home-use study, board-certified ophthalmologist examinations, visual-acuity testing, participant check-ins, and daily diaries supported use around the eye area - including among contact-lens wearers.
30 completed2 weeksOphthalmologist observedTested as SGF19112-03
0 observed
test-article-related adverse effects
Final ophthalmologist examination
Among 30 completers under the study conditions.
8
contact-lens wearers completed
Included in final assessment
Nine enrolled; eight completed.
SeneGenceReviewClinical Results
Clinical safety-in-use evidence
Three complementary layers of observation supported the final safety conclusion.
01
Ophthalmologist examination
Baseline and two-week examination of upper and lower eyelids and lid margins, conjunctivae, visible corneal anomalies, slit-lamp findings, and the periorbital area.
02
Visual-acuity assessment
A trained evaluator measured visual acuity at baseline and after two weeks; no clinically relevant changes were found.
03
Participant monitoring
A one-week call-in and daily safety diaries captured observations during twice-daily home use.
Descriptive results
| Safety evidence | Finding among 30 completers |
|---|---|
| Ophthalmologist examination | No test-article-related adverse effects observed |
| Visual acuity | No clinically relevant changes |
| One-week check-in | No problems reported |
| Daily safety diaries | No negative safety-related comments |
| Contact-lens subgroup | Eight wearers completed without observed test-article-related adverse effects |
This safety study did not report inferential tests or p-values.
Claims supported by the Essex conclusion
Ophthalmologist-Tested and Safe for Contact Lens Wearers, for the tested formula under the defined two-week conditions.
SeneGenceReviewClinical Results
Technical study record
A signed Essex final report authenticates the safety-in-use conclusion.
Independent laboratoryEssex Testing Clinic, Inc.
Panel / entry21663 / 46915
Sponsor codeS174
Tested articleEye Creme AGE Defense Formula SGF19112-03
Design2-week, single-blind home-use safety evaluation
Population31 enrolled; 30 completed; ages 19-69
UseTwice daily, morning and night
Report date24 January 2022
Independent conclusion
The Essex report concluded that the submitted product was safe for use in the eye area and supported the statements “Ophthalmologist-Tested” and “Safe for Contact Lens Wearers.”
Study application
Results support “Ophthalmologist-Tested” and “Safe for Contact Lens Wearers” for Eye Creme AGE Defense Formula SGF19112-03 under the reported two-week safety-in-use design.
SeneGenceReviewTechnical Evidence
Independent laboratory evidence
Original source pages follow.
View the complete source record.
Original Essex pages follow, preserving the laboratory cover, study metadata, signed investigator approvals, Quality Assurance statement, methods, and aggregate safety findings while excluding participant-identifying tables and administrative forms.
The complete PDF pairs this consumer summary with the selected independent laboratory source pages.
Open full PDF + laboratory sourceLaboratoryEssex Testing Clinic, Inc.
Panel / entry21663 / 46915
Report date24 January 2022
AuthenticationSigned investigators + signed QA statement
Source authentication
The final source includes signed investigator approvals and a signed independent Quality Assurance statement.
Independent laboratory source pages are included in the complete PDF. Participant-identifying information has been removed where indicated; aggregate findings are unchanged.